These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38199921)

  • 1. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
    Muller MP; Navarro C; Wilson SE; Shulha HP; Naus M; Lim G; Padhi S; McGeer A; Finkelstein M; Liddy A; Bettinger JA;
    Vaccine; 2024 Jan; 42(3):535-540. PubMed ID: 38199921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
    Mazzotta V; Lepri AC; Matusali G; Cimini E; Piselli P; Aguglia C; Lanini S; Colavita F; Notari S; Oliva A; Meschi S; Casetti R; Mondillo V; Vergori A; Bettini A; Grassi G; Pinnetti C; Lapa D; Tartaglia E; Gallì P; Mondi A; Montagnari G; Gagliardini R; Nicastri E; Lichtner M; Sarmati L; Tamburrini E; Mastroianni C; Stingone C; Siddu A; Barca A; Fontana C; Agrati C; Girardi E; Vaia F; Maggi F; Antinori A;
    EClinicalMedicine; 2024 Feb; 68():102420. PubMed ID: 38292040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
    Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
    Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study.
    Fontán-Vela M; Hernando V; Olmedo C; Coma E; Martínez M; Moreno-Perez D; Lorusso N; Vázquez Torres M; Barbas Del Buey JF; Roig-Sena J; Pastor E; Galmés Truyols A; Artigues Serra F; Sancho Martínez RM; Latasa Zamalloa P; Pérez Martínez O; Vázquez Estepa A; García Rojas AJ; Barreno Estévez AI; Sánchez-Migallón Naranjo A; Pérez Martín JJ; Peces Jiménez P; Morales Romero R; Castilla J; García Cenoz M; Huerta Huerta M; Boone ALD; Macías Ortiz MJ; Álvarez Río V; Rodríguez Recio MJ; Merino Díaz M; Berradre Sáenz B; Villegas-Moreno MT; Limia A; Diaz A; Monge S;
    Clin Infect Dis; 2024 Feb; 78(2):476-483. PubMed ID: 37864849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia.
    Gilbert M; Ablona A; Chang HJ; Grennan T; Irvine MA; Sarai Racey C; Salway T; Naus M; Dawar M; Ogilvie G
    Vaccine; 2023 Apr; 41(15):2485-2494. PubMed ID: 36894397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of mpox infection in individuals who received a first dose of modified vaccinia Ankara immunisation.
    Agunbiade S; Burton F; Muirhead J; Whitlock GG; Girometti N
    Sex Transm Infect; 2023 May; 99(3):198-199. PubMed ID: 36596674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV.
    Raccagni AR; Diotallevi S; Lolatto R; Lucente MF; Candela C; Gianotti N; Trentacapilli B; Canetti D; Castagna A; Nozza S
    AIDS; 2023 Dec; 37(15):2365-2369. PubMed ID: 37773029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox.
    Deng L; Lopez LK; Glover C; Cashman P; Reynolds R; Macartney K; Wood N
    JAMA; 2023 Jun; 329(23):2091-2094. PubMed ID: 37145654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
    Payne AB; Ray LC; Cole MM; Canning M; Houck K; Shah HJ; Farrar JL; Lewis NM; Fothergill A; White EB; Feldstein LR; Roper LE; Lee F; Kriss JL; Sims E; Spicknall IH; Nakazawa Y; Gundlapalli AV; Shimabukuro T; Cohen AL; Honein MA; Mermin J; Payne DC
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(49):1560-1564. PubMed ID: 36480479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the acute antibody response of monkeypox and MVA-BN vaccine following an Australian outbreak.
    Asquith W; Hueston L; Dwyer D; Kok J; Ko D; Fennel M; Rockett R; Rai NJ; Li Y; Sriramoju S; Sutor A; O'Sullivan M
    J Med Virol; 2024 Jan; 96(1):e29407. PubMed ID: 38240403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of a single dose of mpox vaccine in males.
    Wolff Sagy Y; Zucker R; Hammerman A; Markovits H; Arieh NG; Abu Ahmad W; Battat E; Ramot N; Carmeli G; Mark-Amir A; Wagner-Kolasko G; Duskin-Bitan H; Yaron S; Peretz A; Arbel R; Lavie G; Netzer D
    Nat Med; 2023 Mar; 29(3):748-752. PubMed ID: 36720271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022.
    Rosenberg ES; Dorabawila V; Hart-Malloy R; Anderson BJ; Miranda W; O'Donnell T; Gonzalez CJ; Abrego M; DelBarba C; Tice CJ; McGarry C; Mitchell EC; Boulais M; Backenson B; Kharfen M; McDonald J; Bauer UE
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):559-563. PubMed ID: 37339074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
    Merad Y; Gaymard A; Cotte L; Perpoint T; Alfaiate D; Godinot M; Becker A; Cannesson O; Batalla AS; Oria-Yassir F; Landré S; Morfin F; Bouscambert M; Valour F; Ader F; Conrad A
    Euro Surveill; 2022 Dec; 27(50):. PubMed ID: 36695469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
    Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ;
    MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study.
    Sadarangani M; Soe P; Shulha HP; Valiquette L; Vanderkooi OG; Kellner JD; Muller MP; Top KA; Isenor JE; McGeer A; Irvine M; De Serres G; Marty K; Bettinger JA;
    Lancet Infect Dis; 2022 Nov; 22(11):1553-1564. PubMed ID: 35964614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
    Volkmann A; Williamson AL; Weidenthaler H; Meyer TPH; Robertson JS; Excler JL; Condit RC; Evans E; Smith ER; Kim D; Chen RT;
    Vaccine; 2021 May; 39(22):3067-3080. PubMed ID: 33077299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023.
    Dalton AF; Diallo AO; Chard AN; Moulia DL; Deputy NP; Fothergill A; Kracalik I; Wegner CW; Markus TM; Pathela P; Still WL; Hawkins S; Mangla AT; Ravi N; Licherdell E; Britton A; Lynfield R; Sutton M; Hansen AP; Betancourt GS; Rowlands JV; Chai SJ; Fisher R; Danza P; Farley M; Zipprich J; Prahl G; Wendel KA; Niccolai L; Castilho JL; Payne DC; Cohn AC; Feldstein LR; ;
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):553-558. PubMed ID: 37200229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
    Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
    N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.